AMENDMENTS TO THE CLAIMS

1. (Currently Amended) Vinflunine pharmaceutical composition, wherein it is in the form of a stable and sterile aqueous solution of a water-soluble vinflunine salt at a pH of between 3 and 4 and wherein the composition does not contain any preservatives.

2. (Previously Presented) Composition according to Claim 1, wherein the vinflunine salt is vinflunine ditartrate.

3. (Previously Presented) Composition according to Claim 2, wherein the composition consists of vinflunine ditartrate and water for an injectable preparation.

4. (Previously Presented) Composition according to Claim 1, wherein it comprises a pH buffer system in order to maintain the pH between 3 and 4.

5. (Previously Presented) Composition according to Claim 4, wherein the molarity of the pH buffer system is between 0.002 M and 0.2 M.

6. (Previously Presented) Composition according to Claim 4, wherein the pH buffer system consists of an acetic acid/sodium acetate buffer or a citric acid/sodium citrate buffer.

7. (Previously Presented) Composition according to Claim 2, wherein the composition contains vinflunine ditartrate with a base vinflunine concentration of between 1 and 50 mg/ml.

8. (Previously Presented) Composition according to Claim 2, wherein it corresponds to one of the following formulations: 68.35 mg of vinflunine ditartrate qs 2 ml in water or 136.70 mg of vinflunine ditartrate qs 4 ml of water or 341.75 mg of vinflunine ditartrate qs 10 ml of water, the vinflunine ditartrate corresponding, respectively, to 50 mg of base vinflunine, 100 mg of base vinflunine and 250 mg of base vinflunine.

9. (Previously Presented) Composition according to claim 1, wherein it remains stable for at least 36 months at 5°C±3°C.

10. (Previously Presented) Method for treating cancer comprising the parenteral administration of an effective amount of a composition according to Claim 1 to a patient in need thereof.

11. (Canceled).

12. (Previously Presented) Process for preparing a composition according to Claim 1, comprising the following successive steps:

- (a) dissolution of the vinflunine salt in water for injectable preparations,
- (b) optional addition of a pH buffer,
- (c) sterilization by filtration of the bulk solution,
- (d) aseptic distribution, under a nitrogen atmosphere, of the sterile composition obtained in step (c) in the container, advantageously chosen from glass phials, glass bottles and prefilled syringes.

13. (Previously Presented) Packaging container containing the composition according to Claim 1.

14. (Previously Presented) Composition according to claim 7, wherein it contains vinflunine ditartrate with a base vinflunine concentration of between 25 and 30 mg/ml.

15. (Previously Presented) Composition according to claim 14, wherein it contains vinflunine ditartrate with a base vinflunine concentration of 25 mg/ml.

16. (Previously Presented) Method for treating cancer according to claim 10, wherein the parenteral administration is via intravenous perfusion.